Sales fuel earnings growth at Pfizer, Lilly, Wyeth, Novartis, Schering-Plough

Rises in prescription drug sales contributed to robust third-quarter earnings growth posted by Pfizer, Lilly, Wyeth, Novartis and Schering-Plough. Pfizer’s global prescription drug sales rose 10% in the third-quarter to $12.3 billion. Global sales of Lipitor defied generic Zocor, rising 15% in the third-quarter to $3.3 billion Sales of Lyrica and Celebrex helped make up for some of the revenue lost to new generic competition to antibiotic Zithromax and antidepressant Zoloft, Pfizer said. Lilly’s third-quarter global sales were up 7% to $3.9 billion in the third-quarter, driven by Cymbalta and Zyprexa, the company said. Global sales of Cymbalta surged 91% to $348 million, a benefit of Lilly’s sales force reorganization, analysts said, while Zyprexa rose 5% to $1.1 billion, the first increase in six quarters. Lilly unveiled plans last week to purchase ICOS, co-marketer of its erectile dysfunction drug Cialis. Global sales of Cialis increased 26% to $246 million in the third-quarter. Wyeth said third-quarter sales of its Prevnar pneumococcus vaccine rose 30% to $510 million. Global sales of Wyeth’s top-selling product, Effexor, rose 7% to $924 million despite the introduction of generic Zoloft. Novartis said third-quarter global sales increased 13% to $9.5 billion, boosted by sales of its heart drug Diovan. Revenue from Diovan was at $1.1 billion for the third-quarter of 2006, compared to $925 million in the year-ago period, Novartis said. Merck's fortunes may be tied in part to Schering-Plough through the companies' cholesterol joint venture, but the two firms posted divergent earnings. Merck’s third-quarter profit fell 34% partly due to Zocor going off patent. Zocor sales dipped 65% to $371 million from $1 billion in the same period last year. Cholesterol drugs Vytorin and Zetia did well, with Vytorin sales rising 92% to $526.6 million and Zetia sales increasing 41% to $501.9 million. Other bright spots were sales of allergy medication Singulair, which grew 25% to $868 million and Gardasil, which saw $70 million in sales in its debut quarter. Another reason for Merck's posted loss: legal costs associated with nearly 24,000 Vioxx lawsuits. Still, Wall Street thinks Merck can rise to these challenges; its stock finished up 2.5%. Schering-Plough, meanwhile, saw an earnings boost thanks largely to its cholesterol partnership with Merck. Global sales of Schering-Plough’s Remicade were up 34% to $317 million. Global Nasonex sales rose 30% to $221 million, with U.S. sales climbing 41% to $153 million.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions